HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015)

References

• Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo). 1976;29(12):1346–1348.
   PubMed Web of Science ®Google Scholar
• Alberts AW, Chen J, Kuron G, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A. 1980;77(7):3957–3961.
   PubMed Web of Science ®Google Scholar
• Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003;2(7):517–526.
   PubMed Web of Science ®Google Scholar
• European Association for Cardiovascular P, Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–1818.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–S45.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23.
   PubMed Web of Science ®Google Scholar
• Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genom. 2011;21(5):280–288.
   PubMed Web of Science ®Google Scholar
• Stein EA, Raal FJ. New therapies for reducing low-density lipoprotein cholesterol. Endocrin Metab Clin. 2014;43(4):1007–1033.
   Web of Science ®Google Scholar
• Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58–S71.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015;14(6):935–955.
   PubMed Web of Science ®Google Scholar
• Carter AA. Risk of incident diabetes among patients treated with statins: population based study (vol 346, f2610, 2013). BMJ. 2013;347. Article ID: f4356.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Tziomalos K, et al. Pleiotropic effects of statins - clinical evidence. Curr Pharm Des. 2009;15(5):479–489.
   PubMed Web of Science ®Google Scholar
• Lansberg P. Pleiotropic effects of statins and beyond. Cardiology. 2009;112(1):1–3.
   PubMed Web of Science ®Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol. 2005;45:89–118.
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239.
   PubMed Web of Science ®Google Scholar
• Yeboah J, Sillau S, Delaney JC, et al. Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2015;169(3):387–95e3.
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
   PubMed Web of Science ®Google Scholar
• Pfefferkorn JA. Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review. Expert Opin Ther Pat. 2011;21(2):187–203.
   PubMed Web of Science ®Google Scholar
• Gesto DS, Cerqueira NMFSA, Ramos MJ, et al. Discovery of new druggable sites in the anti-cholesterol target HMG-CoA reductase by computational alanine scanning mutagenesis. J Mol Model. 2014;20(4):2178–2190.
   PubMed Web of Science ®Google Scholar
• Lindsay D, Jackson P, inventor; Redx Pharma Limited (Merseybio Incubator Crown Street, Liverpool L69 7ZD, GB), assignee. Use of atorvastatin lactols as medicaments. Patent EP2405911. 2013.
   Google Scholar
• Lindsay D, Jackson P, inventor; RedX Pharma Limited (Manchester, GB), assignee. Use of rosuvastatin lactols as medicaments. United States patent 9102656. 2015.
   Google Scholar
• Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26–37.
   PubMed Web of Science ®Google Scholar
• Roth BD, Blankley CJ, Chucholowski AW, et al. Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus. J Med Chem. 1991;34(1):357–366.
   PubMed Web of Science ®Google Scholar
• Wu F, Wang Z, Li B, et al., inventors; Polysubstitution pyrroles pitavastatin lactone dewatering compound and application thereof. Patent CN104356118A. 2015.
   Google Scholar
• Lindsay D, Jackson P, Hindley S, et al., inventor; BRADFORD PHARMA LIMITED (Douglas Bank House, Wigan Lane, Wigan WN1 2TB, GB), Lindsay, Derek (Bradford Pharma Limited, Douglas Bank HouseWigan Lane, Wigan WN1 2TB, GB), Jackson, Peter (Bradford Pharma Limited, Douglas Bank HouseWigan Lane, Wigan WN1 2TB, GB), Hindley, Stephen (Bradford Pharma Limited, Douglas Bank HouseWigan Lane, Wigan WN1 2TB, GB), Bhamra, Inder (Bradford Pharma Limited, Douglas Bank HouseWigan Lane, Wigan WN1 2TB, GB), assignee. Rosuvastatin and atorvastatin derivatives. Patent WO/2010/103318. 2010.
   Google Scholar
• Wu Fanhong WZ, Bing L, Dandan L, et al., inventor; Polysubstitution miazines pitavastatin lactone dewatering compound and application thereof. Patent CN104356119A. 2014.
   Google Scholar
• Lin J-H, Chen C-C, Fang J-M, et al., inventor; Academia Sinica (Taipei, TW), National Taiwan University (Taipei, TW), assignee. Dual action inhibitors against histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase. United States patent 9115116. 2015.
   Google Scholar
• Chen JB, Chern TR, Wei TT, et al. Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment. J Med Chem. 2013;56(9):3645–3655.
   PubMed Web of Science ®Google Scholar
• Lin YC, Lin JH, Chou CW, et al. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res. 2008;68(7):2375–2383.
   PubMed Web of Science ®Google Scholar
• Gan Y, Wang J, Coselli J, et al. Synergistic induction of apoptosis by HMG-CoA reductase inhibitor and histone deacetylases inhibitor in HeLa cells. Biochem Biophys Res Commun. 2008;365(2):386–392.
   PubMed Web of Science ®Google Scholar
• Jakobisiak M, Golab J. Statins can modulate effectiveness of antitumor therapeutic modalities. Med Res Rev. 2010;30(1):102–135.
   PubMed Web of Science ®Google Scholar
• Wang Zhonghua WF, Bing L, Xiaodong Y, et al., inventor; Polysubstituted phenanthrene ring statin lactone dehydrated compounds and application thereof. Patent CN104311517A. 2014.
   Google Scholar
• Wang Zhonghua WF, Bing L, Xiaodong Y, et al., inventor; Polysubstitution quinolines pitavastatin lactone dewatering compound and application thereof. Patent CN104356120 A. 2014.
   Google Scholar
• Cai Zhengyan ZW, Qun H, inventor; Quinoline compounds, intermediates, preparation methods and uses thereof. Patent US20110046379 A1. 2011.
   Google Scholar
• Cai Zhengyan ZW, Qun H, inventor; Quinoline compounds, intermediates, preparation methods and uses thereof. Patent US8349867 B2. 2011.
   Google Scholar
• Cai Zhengyan ZW, Qun H, inventor; Quinolines compounds and their intermediates, preparation method and application. Patent CN101210011B. 2006.
   Google Scholar
• Cai Z, Zhou W, Hao Q, inventor; Quinoline compounds, intermediates, preparation methods and uses thereof. Patent WO2008077305 A1. 2006.
   Google Scholar
• Zhao Shikui ZW, Jieying T, inventor; 2-cyclopropyl-4-substituted thiophenyl quinoline compounds as well as intermediate, preparation method and application thereof. Patent CN101955477 B. 2009.
   Google Scholar
• Zhao Shikui ZW, Jieying T, inventor; 2-cyclopropyl-4-substituted thiophenyl quinoline compounds as well as intermediate, preparation method and application thereof. Patent CN101955477A. 2009.
   Google Scholar
• Zhao Shikui ZW, Xiangguo M, Di M, et al., inventor; 2-cyclopropyl-4-(N-methyl substituted anilino) quinoline compound as well as intermediate, preparation method and application thereof. Patent CN101967123 B. 2009.
   Google Scholar
• Zhao Shikui ZW, Xiangguo M, Di M, et al., inventor; 2-cyclopropyl-4-(N-methyl substituted anilino) quinoline compound as well as intermediate, preparation method and application thereof. Patent CN101967123 A. 2009.
   Google Scholar
• Cai Zhengyan ZW, Guifang S, Jieying T, et al., inventor; Quinoline derivative as well as preparation method thereof, midbody and application thereof. Patent CN102442997 A. 2010.
   Google Scholar
• Cai Zhengyan ZW, Guifang S, Jieying T, et al., inventor; Quinoline derivative as well as preparation method thereof, midbody and application thereof. Patent CN102442997 B. 2010.
   Google Scholar
• Cai Zhengyan ZW, Shikui Z, Xiaotian Z, et al., inventor; 2-cyclopropyl-4-substituted-phenoxy-quinoline derivatives, and its preparation method, intermediate and application. Patent CN102477032 A. 2010.
   Google Scholar
• Cai Zhengyan ZW, Shikui Z, Xiaotian Z, et al., inventor; 2-cyclopropyl-4-substituted-phenoxy-quinoline derivatives, and its preparation method, intermediate and application. Patent CN102477032 B. 2010.
   Google Scholar
• Hao Qun CZ, Weicheng Z, Jing P, et al., inventor; Substituted quinoline compound, and preparation method, medicine combination and application thereof. Patent CN102816203 A. 2011.
   Google Scholar
• Hao Qun CZ, Weicheng Z, Jing P, et al., inventor; Substituted quinoline compound, and preparation method, medicine combination and application thereof. Patent CN102816203 B. 2011.
   Google Scholar
• Zhang L, Li J, Li H, inventors; Application of 4,5,6,7-tetrahydro pravastatin and salts thereof in cardiovascular diseases. Patent CN 102875504 A. 2013.
   Google Scholar
• Wu Fanhong WX, Xiang F, Yuanyuan X, et al., inventor; 4-subsititued 3,5-dihydroxy carboxylic acid compound and preparation method thereof. Patent CN102153463 A. 2011.
   Google Scholar
• Wu Fanhong WX, Xiang F, Yuanyuan X, et al., inventor; 5-fluorine-substituted 4-hydroxyl-3,4,5,6-tetrahydro-2H-pyrane-2-ketone compound and preparation method thereof. Patent CN102086184 A. 2011.
   Google Scholar
• Wu Fanhong WZ, Bing L, Xiaodong Y, et al., inventor; Poly-substituted indole statin lactone dehydrated compound and use thereof. Patent CN104327057 A. 2014.
   Google Scholar
• Duan Zhenwen GS, Xuemei L, inventor; Beijing Peking University WBL Biotech Co., Ltd. (Block A, Room 701-705No.30 South Haidian Road, Haidian District, Beijing 0, 100080, CN), assignee. Sterols derivative, and preparation method and purpose thereof patent. WO/2013/097681. 2013.
   Google Scholar
• Duan Z, Guo S, Li X, inventor; Beijing Peking University WBL Biotech Co., Ltd., assignee. Sterol derivative, preparation method therefor and use thereof. United States patent 20150025130. 2015.
   Google Scholar
• Potter SM. Soy protein and cardiovascular disease: the impact of bioactive components in soy. Nutr Rev. 1998;56(8):231–235.
   PubMed Web of Science ®Google Scholar
• Lovati MR, Manzoni C, Canavesi A, et al. Soybean protein diet increases low density lipoprotein receptor activity in mononuclear cells from hypercholesterolemic patients. J Clin Invest. 1987;80(5):1498–1502.
   PubMed Web of Science ®Google Scholar
• Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333(5):276–282.
   PubMed Web of Science ®Google Scholar
• Baum JA, Teng H, Erdman JW Jr, et al. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am J Clin Nutr. 1998;68(3):545–551.
   PubMed Web of Science ®Google Scholar
• Wong WW, Smith EO, Stuff JE, et al. Cholesterol-lowering effect of soy protein in normocholesterolemic and hypercholesterolemic men. Am J Clin Nutr. 1998;68(6 Suppl):1385S–1389S.
   PubMed Web of Science ®Google Scholar
• Galvez AF, inventor; Methods for using soy peptides to inhibit h3 acetylation, reduce expression of HMG-coA reductase and increase ldl receptor and sp1 expression in a mammal patent. WO 2008034117 A2. 2008.
   Google Scholar
• Galvez AF, inventor; Products and methods using soy peptides to lower total and ldl cholesterol levels. Patent CA 2664066 A1. 2008.
   Google Scholar
• Lovati MR, Manzoni C, Gianazza E, et al. Soy protein peptides regulate cholesterol homeostasis in Hep G2 cells. J Nutr. 2000;130(10):2543–2549.
   PubMed Web of Science ®Google Scholar
• Lammi C, Zanoni C, Arnoldi A, et al. Two peptides from soy β-conglycinin induce a hypocholesterolemic effect in HepG2 cells by a statin-like mechanism: comparative in vitro and in silico modeling studies. J Agric Food Chem. 2015;63(36):7945–7951.
   PubMed Web of Science ®Google Scholar
• Lammi C, Zanoni C, Arnoldi A. Three peptides from soy glycinin modulate glucose metabolism in human hepatic HepG2 cells. Int J Mol Sci. 2015;16(11):27362–27370.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ledesma B, De Lumen BO. Lunasin: a novel cancer preventive seed peptide. Perspect Medicin Chem. 2008;2:75–80.
   PubMedGoogle Scholar
• Lule VK, Garg S, Pophaly SD, et al. Potential health benefits of lunasin: a multifaceted soy-derived bioactive peptide. J Food Sci. 2015;80(3):R485–94.
   PubMed Web of Science ®Google Scholar
• Galvez AF, inventor; Methods for using soy peptides to inhibit H3 acetylation, reduce expression of HMG CoA reductase, and increase LDL receptor and Sp1 expression in a mammal. Patent US7731995 B2. 2010.
   Google Scholar
• Galvez AF, Schmidt R, Hastings C, inventors; Products and methods using lunasin-enriched soy extract mixtures to reduce free fatty acid levels, increase leptin levels and increase adiponectin levels in plasma. Patent WO2014145086 A2. 2014.
   Google Scholar
• Galvez AF, inventor; Use of soy peptide (lunasin) to lower total and ldl cholesterol levels. Patent EP20070842567. 2013.
   Google Scholar
• Zhang Y, Wang W, Wang J, inventors; Dipeptide DI with double functions of reducing blood sugar and blood fat and application thereof. Patent CN20141245686 20140604. 2014.
   Google Scholar
• Wang W, Wang N, Zhang Y, et al., inventors; Dipeptide SD with dual functions of lowering blood pressure and blood fat and application thereof. Patent CN20131750012 20131230. 2013.
   Google Scholar
• Wang W, Wang N, Zhang Y, et al., inventors; Dipeptide QD with double functions of lowering blood pressure and lowering blood fat and application thereof. Patent CN 103755783 A. 2014.
   Google Scholar
• Wang W, Wang N, Zhang Y, et al., inventors; Dipeptide ST with double functions of lowering blood pressure and lowering blood fat and application thereof. Patent CN 103755782 A. 2014.
   Google Scholar
• Wang W, Wang N, Zhang Y, et al., inventors; Dipeptide DL with double functions of lowering blood pressure and lowering blood fat and application thereof. Patent CN 103736076 B. 2015.
   Google Scholar
• Pak VV, Kim SH, Koo M, et al. Peptide design of a competitive inhibitor for HMG-CoA reductase based on statin structure. Biopolymers. 2006;84(6):586–594.
   PubMed Web of Science ®Google Scholar
• Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007;12:34–42.
   PubMed Web of Science ®Google Scholar
• Maehre HK, Jensen I-J, Elvevoll EO, et al. ω-3 fatty acids and cardiovascular diseases: effects, mechanisms and dietary relevance. Int J Mol Sci. 2015;16:22636–22661.
   PubMed Web of Science ®Google Scholar
• Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Postgrad Med. 2014;126:7–18.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Phillips AK, Kling D, et al. Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia. Expert Rev Cardiovasc Ther. 2014;12:1045–1054.
   PubMedGoogle Scholar
• Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101:S20–S26.
   PubMed Web of Science ®Google Scholar
• Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210:353–361.
   PubMed Web of Science ®Google Scholar
• Keene D, Price C, Shun-Shin MJ, et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients. BMJ. 2014;349:g4379.
   PubMed Web of Science ®Google Scholar
• Ibrahim MM. RAS inhibition in hypertension. J Hum Hypertens. 2006;20:101–108.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Katsiki N, Karagiannis A, et al. Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease. Curr Pharm Des. 2014;20:6299–6305.
   PubMed Web of Science ®Google Scholar
• Koh KK, Sakuma I, Hayashi T, et al. Renin–angiotensin system inhibitor and statins combination therapeutics – what have we learnt? Expert Opin Pharmacother. 2015;16:949–953.
   PubMed Web of Science ®Google Scholar
• Couture P, Lamarche B. Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond. Curr Opin Lipidol. 2013;24:227–232.
   PubMed Web of Science ®Google Scholar
• Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases. J Lipid Res. 2012;53:2515–2524.
   PubMed Web of Science ®Google Scholar
• Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010;9:154–169.
   PubMed Web of Science ®Google Scholar
• Farooqui AA, Ong W-Y, Horrocks LA, et al. Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans. Brain Res Rev. 2007;56(2):443–471.
   PubMedGoogle Scholar
• Ling Q, Tejada-Simon MV. Statins and the brain: new perspective for old drugs. Prog Neuropsychopharmacol Biol Psychiatry. 2016;66:80–86.
   PubMed Web of Science ®Google Scholar
• Cerezo-Guisado MI, Garcia-Roman N, Garcia-Marin LJ, et al. Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts. Biochem J. 2007;401:175–183.
   PubMed Web of Science ®Google Scholar
• Tejada-Simon MV. Modulation of actin dynamics by Rac1 to target cognitive function. J Neurochem. 2015;133(6):767–779.
   PubMed Web of Science ®Google Scholar
• Roy A, Jana M, Kundu M, et al. HMG-CoA reductase inhibitors bind to PPARα to upregulate neurotrophin expression in the brain and improve memory in mice. Cell Metabolism. 2015;22(2):253–265.
   PubMed Web of Science ®Google Scholar
• Chen LY, Haught WH, Yang BC, et al. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol. 1997;30(2):569–575.
   PubMed Web of Science ®Google Scholar
• Antonopoulos AS, Margaritis M, Lee R, et al. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519–1530.
   PubMed Web of Science ®Google Scholar
• Vallianou NG, Kostantinou A, Kougias M, et al. Statins and cancer. Anticancer Agents Med Chem. 2014;14(5):706–712.
   PubMed Web of Science ®Google Scholar
• Chogtu B, Magazine R, Bairy KL. Statin use and risk of diabetes mellitus. World J Diabetes. 2015;6(2):352–357.
   PubMed Web of Science ®Google Scholar
• Yuan C, Zhou L, Cheng J, et al. Statins as potential therapeutic drug for asthma? Respir Res. 2012;13:375–385.
   PubMed Web of Science ®Google Scholar
• Walker DY, Edwards KL. Statins in the treatment of asthma. Am J Health-System Pharm. 2013;70(19):1661–1669.
   PubMed Web of Science ®Google Scholar
• Yudoh K, Karasawa R. Statin prevents chondrocyte aging and degeneration of articular cartilage in osteoarthritis (OA). Aging-Us. 2010;2(12):990–998.
   Web of Science ®Google Scholar
• Shah SR, Werlang CA, Kasper FK, et al. Novel applications of statins for bone regeneration. Natl Sci Rev. 2015;2(1):85–99.
   PubMed Web of Science ®Google Scholar
• Paul R, Choudhury A, Borah A. Cholesterol - a putative endogenous contributor towards Parkinson’s disease. Neurochem Int. 2015;90:125–133.
   PubMed Web of Science ®Google Scholar
• Tsai S-J. Statins may enhance the proteolytic cleavage of proBDNF: implications for the treatment of depression. Med Hypotheses. 2007;68(6):1296–1299.
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723–749.
   PubMed Web of Science ®Google Scholar
• Kirby TJ. Cataracts produced by triparanol. (MER-29). Trans Am Ophthalmol Soc. 1967;65:494–543.
   PubMedGoogle Scholar